FDA Grants Emergency Approval for Sanofi’s New Drug Combo: Multiple Myeloma Patients Face New Risks—Is Disease Progression Risk Reduced by 40%?

The U.S. Food and Drug Administration (FDA) announced on Friday that it has approved a new drug combination that will be used in combination with Sarclisa infusion, made by Sanofi, to treat certain newly diagnosed multiple myeloma patients. Sarclisa has previously been approved by the FDA for multiple myeloma cases that require backup treatment after standard treatment options have failed.

As a market leader in anti-inflammatory drugs, the French pharmaceutical company has always emphasized its commitment to oncology drug development. Despite the failure of the company's once-promising breast cancer drug candidate in 2022, Sanofi has not abandoned its research and development in the oncology drug space.

The FDA's latest approval means that there is now a new treatment option for patients with multiple myeloma who are not candidates for autologous stem cell transplantation. Autologous stem cell transplantation is a common treatment for multiple myeloma in which a patient's own healthy blood cells are transplanted to restore bone marrow function.

In a late-stage study, a specific treatment regimen with Sarclisa reduced the risk of disease progression or death by 40 percent compared to a regimen without Sarclisa. The study was conducted in patients who are not candidates for autologous stem cell transplantation, which would not restore bone marrow function.

Sarclisa received priority review status from the FDA in May, indicating that the FDA is paying high attention to the potential efficacy and safety of this drug. Sanofi plans to continue advancing its blood cancer drugs known as anti-CD38, which include Sarclisa. Although competitors GenMab and Johnson & Johnson have also made significant progress in the same category, Sanofi remains confident in Sarclisa's market prospects.

According to LSEG, Sarclisa generated sales of 227 million euros ($253.4 million) in the first half of the year. Analysts expect annual sales of Sarclisa to reach €800 million to €900 million by 2030, showing the strong demand and broad prospects for the drug.